Biovaxys Technology Corp (BIOV)

0.130
+0.010(+8.33%)
  • Volume:
    47,003
  • Bid/Ask:
    0.125/0.130
  • Day's Range:
    0.125 - 0.135

BIOV Overview

Prev. Close
0.12
Day's Range
0.125-0.135
Revenue
-
Open
0.125
52 wk Range
0.09-0.65
EPS
-0.06
Volume
47,003
Market Cap
12.91M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
58,917
P/E Ratio
-
Beta
-
1-Year Change
-47.83%
Shares Outstanding
103,280,845
Next Earnings Date
-
What is your sentiment on Biovaxys Technology?
or
Market is currently closed. Voting is open during market hours.

Biovaxys Technology Corp News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Biovaxys Technology Corp Company Profile

Biovaxys Technology Corp Company Profile

Employees
0
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA09076M1014
  • CUSIP:09076M101

BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyNeutralSellSell
Technical IndicatorsStrong BuyStrong BuyNeutralSellStrong Sell
SummaryStrong BuyStrong BuyNeutralSellStrong Sell